Table 3. Response to Ipilimumab and Anti–Programmed Cell Death 1 Therapy.
Response | Patients, No. (%) | |
---|---|---|
Ipilimumab therapy | Anti–programmed cell death 1 therapy | |
Complete response | 3 (5) | 10 (18) |
Partial response | 5 (9) | 14 (25) |
Stable disease | 15 (27) | 13 (23) |
Progression | 31 (55) | 16 (29) |
Not evaluated | 2 (4) | 3 (5) |